BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 27573644)

  • 1. Clinical Implications of Hepatocyte Growth Factor, Interleukin-20, and Interleukin-22 in Serum and Bronchoalveolar Fluid of Patients with Non-Small Cell Lung Cancer.
    Naumnik W; Naumnik B; Niklińska W; Ossolińska M; Chyczewska E
    Adv Exp Med Biol; 2016; 952():41-49. PubMed ID: 27573644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel cytokines: IL-27, IL-29, IL-31 and IL-33. Can they be useful in clinical practice at the time diagnosis of lung cancer?
    Naumnik W; Naumnik B; Niewiarowska K; Ossolinska M; Chyczewska E
    Exp Oncol; 2012 Dec; 34(4):348-53. PubMed ID: 23302994
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Significance of HMGB-1 and TGF-β Level in Serum and BALF of Advanced Non-Small Cell Lung Cancer.
    Jakubowska K; Naumnik W; Niklińska W; Chyczewska E
    Adv Exp Med Biol; 2015; 852():49-58. PubMed ID: 25753556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum hepatocyte growth factor and interleukin-6 are effective prognostic markers for non-small cell lung cancer.
    Ujiie H; Tomida M; Akiyama H; Nakajima Y; Okada D; Yoshino N; Takiguchi Y; Tanzawa H
    Anticancer Res; 2012 Aug; 32(8):3251-8. PubMed ID: 22843899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Evaluation of IL-6 level in serum and bronchoalveolar lavage fluid of patients with non-small cell lung cancer (NSCLC)].
    Huang F; Wang XL; Geng Y; Li MX
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2005 Jul; 21(4):507-9. PubMed ID: 15989803
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of serum vascular endothelial growth factor and interleukin-6 on treatment response to epidermal growth factor receptor tyrosine kinase inhibitors in patients with non-small-cell lung cancer.
    Jia Y; Li X; Zhao C; Jiang T; Zhao S; Zhang L; Liu X; Shi J; Qiao M; Luo J; Liu S; Han R; Chen X; Zhou C
    Lung Cancer; 2018 Nov; 125():22-28. PubMed ID: 30429024
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical significance of serum hepatocyte growth factor and epidermal growth factor gene somatic mutations in patients with non-squamous non-small cell lung cancer receiving gefitinib or erlotinib.
    Masago K; Togashi Y; Fujita S; Sakamori Y; Okuda C; Kim YH; Mio T; Mishima M
    Med Oncol; 2012 Sep; 29(3):1614-21. PubMed ID: 21779929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiogenic axis angiopoietin-1 and angiopoietin-2/Tie-2 in non-small cell lung cancer: a bronchoalveolar lavage and serum study.
    Naumnik W; Naumnik B; Niewiarowska K; Ossolinska M; Chyczewska E
    Adv Exp Med Biol; 2013; 788():341-8. PubMed ID: 23835996
    [TBL] [Abstract][Full Text] [Related]  

  • 9. B Cell-Attracting Chemokine-1 and Progranulin in Bronchoalveolar Lavage Fluid of Patients with Advanced Non-small Cell Lung Cancer: New Prognostic Factors.
    Naumnik W; Panek B; Ossolińska M; Naumnik B
    Adv Exp Med Biol; 2019; 1150():11-16. PubMed ID: 30357709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Measurement of hepatocyte growth factor in serum and bronchoalveolar lavage fluid in patients with pulmonary fibrosis.
    Yamanouchi H; Fujita J; Yoshinouchi T; Hojo S; Kamei T; Yamadori I; Ohtsuki Y; Ueda N; Takahara J
    Respir Med; 1998 Feb; 92(2):273-8. PubMed ID: 9616525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum IL-33 as a diagnostic and prognostic marker in non- small cell lung cancer.
    Hu LA; Fu Y; Zhang DN; Zhang J
    Asian Pac J Cancer Prev; 2013; 14(4):2563-6. PubMed ID: 23725175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interleukin-17 levels correlate with poor prognosis and vascular endothelial growth factor concentration in the serum of patients with non-small cell lung cancer.
    Pan B; Che D; Cao J; Shen J; Jin S; Zhou Y; Liu F; Gu K; Man Y; Shang L; Yu Y
    Biomarkers; 2015; 20(4):232-9. PubMed ID: 26301881
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased IL-10+CD206+CD14+M2-like macrophages in alveolar lavage fluid of patients with small cell lung cancer.
    Hu X; Gu Y; Zhao S; Hua S; Jiang Y
    Cancer Immunol Immunother; 2020 Dec; 69(12):2547-2560. PubMed ID: 32583155
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum vascular endothelial growth factor and COX-2/5-LOX inhibition in advanced non-small cell lung cancer: Cancer and Leukemia Group B 150304.
    Edelman MJ; Hodgson L; Wang X; Christenson R; Jewell S; Vokes E; Kratzke R
    J Thorac Oncol; 2011 Nov; 6(11):1902-6. PubMed ID: 21964530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gemcitabine inhibits the micrometastasis of non-small cell lung cancer by targeting the EpCAM-positive circulating tumor cells via the HGF/cMET pathway.
    Liao ZJ; Guo YH; Zhao Z; Yao JT; Xu R; Nan KJ
    Int J Oncol; 2014 Aug; 45(2):651-8. PubMed ID: 24867356
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of circulating angiogenic biomarkers from patients in two phase III trials in lung cancer of chemotherapy alone or chemotherapy and thalidomide.
    Young RJ; Tin AW; Brown NJ; Jitlal M; Lee SM; Woll PJ
    Br J Cancer; 2012 Mar; 106(6):1153-9. PubMed ID: 22353811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatocyte growth factor in exhaled breath and BAL fluid in sarcoidosis.
    Piotrowski WJ; Kurmanowska Z; Antczak A; Marczak J; Górski P
    Pneumonol Alergol Pol; 2010; 78(3):187-91. PubMed ID: 20461686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased levels of vascular endothelial growth factor in bronchoalveolar lavage of patients with bronchial carcinoma effect of tumour activity and oxidative stress due to radio-chemotherapy?
    Beinert T; Binder D; Oehm C; Ziemer S; Priem F; Schweigert M; Stuschke M; Fleischhacker M; Siebert G; Mergenthaler HG; Werner TG; Sezer O; Possinger K
    Eur J Med Res; 1999 Aug; 4(8):328-34. PubMed ID: 10471544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic Value of Osteoprotegerin and sRANKL in Bronchoalveolar Lavage Fluid of Patients with Advanced Non-small Cell Lung Cancer.
    Naumnik W; Płońska I; Ossolińska M; Nikliński J; Naumnik B
    Adv Exp Med Biol; 2018; 1047():1-6. PubMed ID: 29052177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum levels of interleukin-6 as a prognostic factor in advanced non-small cell lung cancer.
    De Vita F; Orditura M; Auriemma A; Infusino S; Roscigno A; Catalano G
    Oncol Rep; 1998; 5(3):649-52. PubMed ID: 9538169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.